Jennison Associates LLC Makes New $690,000 Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Jennison Associates LLC purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 34,515 shares of the biotechnology company's stock, valued at approximately $690,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. D. E. Shaw & Co. Inc. lifted its holdings in ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company's stock valued at $76,298,000 after purchasing an additional 1,442,799 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock worth $69,454,000 after acquiring an additional 92,281 shares during the last quarter. Driehaus Capital Management LLC boosted its holdings in shares of ADMA Biologics by 17.3% during the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company's stock worth $33,860,000 after acquiring an additional 447,743 shares during the period. Renaissance Technologies LLC grew its position in shares of ADMA Biologics by 28.7% in the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company's stock valued at $28,868,000 after purchasing an additional 575,100 shares during the last quarter. Finally, Federated Hermes Inc. increased its stake in shares of ADMA Biologics by 15.5% during the second quarter. Federated Hermes Inc. now owns 1,969,811 shares of the biotechnology company's stock worth $22,022,000 after purchasing an additional 263,677 shares during the period. Institutional investors own 75.68% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on ADMA shares. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. Raymond James lifted their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th. Finally, HC Wainwright boosted their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the business's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares of the company's stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Adam S. Grossman sold 236,889 shares of the company's stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares of the company's stock, valued at approximately $36,436,552.94. This trade represents a 10.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 421,900 shares of company stock worth $7,445,771. Corporate insiders own 3.70% of the company's stock.

ADMA Biologics Price Performance

ADMA traded down $0.12 during trading on Friday, hitting $21.18. 2,107,830 shares of the stock traded hands, compared to its average volume of 3,886,240. The business has a 50 day moving average price of $18.86 and a 200 day moving average price of $14.89. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a twelve month low of $3.60 and a twelve month high of $23.64. The company has a market cap of $5.01 billion, a price-to-earnings ratio of 75.64 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the previous year, the firm posted $0.01 EPS. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.